Marnetegragene Autotemcel (Kresladi) (CPB 1102)
Aetna's Clinical Policy Bulletin 1102 addresses marnetegragene autotemcel (Kresladi) for commercial medical plans, and it points to the Medicare Part B criteria for Medicare. Precertification is required of all Aetna participating providers and members in applicable plan designs, through National Medical Excellence at 877-212-8811. Unless the member's health plan has elected not to require it, gene and cellular therapies must be administered at an Aetna Institutes GCIT Network, and Aetna considers the one-time administration medically necessary when all listed LAD-I criteria are met.